/
We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation. As pioneers of minimally invasive treatment for sacroiliac joint dysfunction and degeneration, we have developed a deep competency in addressing the challenges of low-density bone in the sacrum.
The business is unprofitable at the operating level (-11.11% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 20.2% YoY with margins expanding 10.0pp.
Negative free cash flow of -$9M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$206M
▲ +20.2% YoY
Net Income (TTM)
-$17M
▲ +38.8% YoY
Op. Margin
-9.67%
▲ +10.0pp YoY
ROIC
-7.39%
▲ +5.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▲ +60.3% YoY
Op. Cash Flow (TTM)
$2M
▲ +94.6% YoY
Net Debt
-$102M
Net Cash Position
Cash & Equiv.
$145M
5Y CAGR: +22.3%
Continue Research